Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2019

View Archived Issues

DNA damage repair protein Mus81 promotes migration of gastric cancer through regulation of ZEB1

TWEAK/Fn14 is upregulated in Crohn's disease and has a key pathogenic role in ileitis mouse models

Xeris initiates dosing in phase II study of fixed-ratio coformulation of pramlintide and insulin

A pancreatic (pro)enzyme mixture shows high efficacy against human pancreatic cancer stem cells

CAFs 'educated' by GoF p53-mutant pancreatic cancer cells promote metastasis and chemoresistance

Novel glomerulus-on-a-chip for renal disease modeling and drug testing

Boehringer and Inflammasome partner to develop novel therapies for retinal diseases

CStone announces clinical data for CS-1001, CS-1002 and CS-1003

FDA approves Pifeltro and Delstrigo for virologically suppressed adults with HIV-1 infection

Phase I data presented from the phase I/II STERIMGLI trial of durvalumab plus hFSRT

Rottapharm Biotech presents CR-13626, an oral tyrosine kinase inhibitor for the treatment of GBM

Karyopharm presents promising phase II safety and efficacy data for selinexor in rGBM

Lenti-D demonstrates the ability to stabilize neurologic disease progression in phase II/III study

Novartis discovers new endonucleases inhibitors

Reaction Biology Corp. describes HDAC/SIRT inhibitors

U.S. Department of Defense awards research grant to Novan

New PD-1 inhibitors disclosed by Bristol-Myers Squibb

Finding a balance in treating diabetic kidney damage

Beijing Scitech-Mq Pharmaceuticals patents wild-type EGFR, EGFR T790M mutant and HER2 inhibitors

DeNovaMed identifies bacterial acyl carrier protein synthase inhibitors

GenSight reports week 96 data from phase III RESCUE trial of GS-010 in LHON

FDA approves Rybelsus for type 2 diabetes

Immune responses, tumor reductions observed with Bria-IMT and pembrolizumab in phase I/IIa study

Phase IIa study assesses efficacy of vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP

Syndax initiates phase I/II study of SNDX-5613 in relapsed or refractory leukemias

Crysvita approved in Japan for FGF-23-related hypophosphatemic rickets and osteomalacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...